NOVO B Novo Nordisk A/S Class B

Notice for the Annual General Meeting of Novo Nordisk A/S

Notice for the Annual General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 21 February 2020 – The Annual General Meeting of Novo Nordisk A/S will be held on:



Thursday 26 March 2020 at 2.00 pm (CET) at Bella Center, Center Boulevard 5, DK-2300 Copenhagen S, Denmark.



The notice for the Annual General Meeting, including Appendix 1: Proposed Remuneration Policy and Appendix 2: Candidates for the Board of Directors is enclosed.

BOARD OF DIRECTORS

All board members elected by the Annual General Meeting are up for election.

The Board of Directors proposes re-election of all board members elected by the Annual General Meeting: Helge Lund (chairman) Jeppe Christiansen (vice chairman), Brian Daniels, Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Liz Hewitt, Kasim Kutay and Martin Mackay.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:  
Mette Kruse Danielsen
Ken Inchausti (US)
   
Investors:  
Daniel Bohsen
Valdemar Borum Svarrer
Ann Søndermølle Rendbæk
Mark Joseph Root
Kristoffer Due Berg (US)

Company announcement No 12 /2020

Attachment

EN
21/02/2020

Underlying

NOVO BNovo Nordisk A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novo Nordisk A/S Class B

Free Trial
NOVO B Novo Nordisk A/...

Novo Nordisk AS: 1 director

A director at Novo Nordisk AS sold 40,000 shares at 450.528DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

NOVO B NOVO NORDISK A/S CLASS B
05/09/25 May 9, 2025 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
NOVO B Novo Nordisk A/...

Zealand Pharma (Buy, TP: DKK950.00) - Dapiglutide likely next catalyst

Q1 revenue missed expectations on lower reimbursement revenue, while operating profit was a beat, as opex was below our forecast and consensus. The 2025 guidance was maintained for opex of DKK2,000m–2,500m. We believe the next potential share-price catalyst is the top-line results from the phase Ib dapiglutide trial in Q2e. We reiterate our BUY, but have cut our target price to DKK950 (1,000).

NOVO B NOVO NORDISK A/S CLASS B
05/08/25 May 8, 2025 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
NOVO B Novo Nordisk A/...

Novo Nordisk (Buy, TP: DKK900.00) - Accelerated Wegovy roll-out ahead

Q1 LCY figures beat our forecasts, while the 2025 guidance was cut to 13–21% LCY sales growth YOY and 16–24% LCY operating profit growth YOY due to weaker GLP-1 sales. We have lowered our rebate for US Ozempic but maintain our 52% Wegovy rebate (in line with the Q1 rebate when adjusting for de-stocking). We reiterate our BUY and DKK900 target price.

NOVO B NOVO NORDISK A/S CLASS B
05/07/25 May 7, 2025 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
NOVO B Novo Nordisk A/...

Novo Nordisk (Buy, TP: DKK900.00) - Underlying soft GLP-1 sales

We forecast a soft Q1, with 17.3% LCY sales growth and 13.8% LCY operating profit growth due to subdued prescriptions. While we estimate Ozempic sales c0.5% below consensus, we are c1.2% above for Wegovy, as we include DKK1bn in sales related to Wegovy US inventories. We see likely relief from potential unchanged 2025 LCY guidance, supported by improved Wegovy supply and fading pressure from compounders. We reiterate our BUY and DKK900 target price.

NOVO B NOVO NORDISK A/S CLASS B
05/01/25 May 1, 2025 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
NOVO B Novo Nordisk A/...

Zealand Pharma (Buy, TP: DKK1000.00) - Focus on pipeline progression

We expect an uneventful Q1 report, with investor focus on top-line results from the dapiglutide phase Ib obesity trial (due in Q2), which could help provide clarity on the positioning of the molecule in obesity and inflammation. For petrelintide, we have reduced our peak sales forecast to cUSD10.0bn (cUSD10.8bn) on increased competition from GUBamy. We reiterate our BUY but have cut our target price to DKK1,000 (1,150).

NOVO B NOVO NORDISK A/S CLASS B
04/30/25 April 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch